Genmab — November 2020

[E_L]

@Solsen isn't that what Judith said in the Q3? "s you see in the expansions, we are enrolling patients that are naive to checkpoint inhibitors in those tumors where the activity for PD-1s or PD-L1s is more sort of low. And in addition, we are enrolling like type tumor types that failed PD-1s, PD-L1s."

[E_L]

i thought it was interesting to hear Jan speak about AbbVie and also their next generation ADC technology. Wondering if we should put this in context with their decision on ADCT/ Cami T

[E_L]

of which they did not speak negatively by the way, Cami came up as another potential future revenue

[E_L]

Jan mentioned 5 Epco trials, where i only see 4, not sure if that was an error or we should see one very soon?

[Solsen]

He also said that the big epco ph 1/2 trial were inrolling in many cohort/indications which could lead to accelerated approval....

[E_L]

yes, it seems ASH could be more interesting as i had anticipated if they can reveal enough data on epco...

[E_L]

they also made me think about Enapotamab again , it has the same warhead as Tisotumab, i wonder if it could be a candidate for another 50:50 with Seagen. They already get a royalty.

[Solsen]

All points at a dead candidate in Enapotamab, I belive.

[E_L]

if they still see sufficient potential, such a partnership could be an elegant solution. We'll find out soon...

[Solsen]

Hope so

[E_L]

Jan said he had a fireside chat toghether with JNJ's Paul Stoffels 2 days ago, has anyone seen that?

[Helge_LarsenPI-redaktør]

We are pleased to share our financial
calendar for 2021. For details, visit https://ir.genmab.com/financial-cale

[E_L]

the new kid on the block with a new Ph2 trial -A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma https://www.clinicaltrials.gov/ct2/show/NCT04634552?term=NCT04634552&draw=2&rank=1

[StockBull]

Wall street targets https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/88705_tipranks.JPG

[Klarussen]

@StockBull, ja, spændende om det er herfra vi skal opad på retracement. Holder nu krudtet tørt indtil videre.

[AaBforever]

Pas nu på du ikke bare venter på Godot..;-)

[E_L]

Blood - A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys https://ash.confex.com/ash/2020/webprogram/Paper137006.html

[E_L]

Novo Q3 "Regarding the FVIII-mimicking antibody project, Mim8, we have despite a COVID-19 related period of delay in phase 1, caught up with the timelines and are now in phase 2 in hemophilia patients with or without inhibitors, hemophilia A patients."

[Klarussen]

Just a moment...

(www.proinvestor.com)

[Klarussen]

Stoxx: Nu skal de europæiske healthcare aktier holde stand, ellers ….